Literature DB >> 11214619

Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.

E Topuz1, A Aydiner, P Saip, Y Eralp, F Taş, Y Salihoğlu, N Tenekeci.   

Abstract

UNLABELLED: The aim of this study was to evaluate the role of serum CA125 levels and computerized tomography (CT) scans in predicting pathologic response of intraperitoneal chemotherapy in patients with ovarian cancer. We prospectively analyzed serum CA125 levels and abdominopelvic CT scans obtained after the completion of intraperitoneal chemotherapy in 52 patients with ovarian cancer and compared the results with subsequent laparotomic findings, which served as the gold standard for statistical analysis. Laparatomy revealed either microscopic or macroscopic residual disease in 20 patients, while 32 patients were completely tumor-free. CA125 levels correlated significantly with laparotomic findings (p=0.003, u=1405). Median CA125 values in patients with residual tumors and in tumor-free patients following intraperitoneal chemotherapy were 14.6 (1-775) and 7.2 (1-37) U/ml, respectively. Although CT-imaging and CA 125 levels had a high specificity (100% and 96.9%, respectively), they showed a low sensitivity rate (50% and 40%, respectively). Similarly, despite high positive predictive values (100% and 88.9%, respectively), the negative predictive values were 76.2% and 72.1%, respectively.
CONCLUSION: Although highly specific, CT scans and CA125 levels do not accurately indicate the presence of disease. Due to a high false-negative rate, a normal CT scan or a normal CA125 value is not sufficient to replace a laparotomy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11214619

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  7 in total

1.  The value of abdominal CT scans in decision-making during chemotherapy in ovarian cancer.

Authors:  M A L van Lankveld; P H M Peeters; M A van Eijkeren; V C M Koot; P O Witteveen; W P Th M Mali
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

2.  Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer.

Authors:  G Mangili; M Picchio; S Sironi; R Viganò; E Rabaiotti; D Bornaghi; V Bettinardi; C Crivellaro; C Messa; F Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-20       Impact factor: 9.236

3.  Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma.

Authors:  María José García-Velloso; Matías Jurado; Carolina Ceamanos; José Manuel Aramendía; María Puy Garrastachu; Guillermo López-García; José Angel Richter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-21       Impact factor: 9.236

Review 4.  Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Authors:  Stavroula Kyriazi; Stan B Kaye; Nandita M deSouza
Journal:  Nat Rev Clin Oncol       Date:  2010-04-13       Impact factor: 66.675

5.  Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?

Authors:  Ahmet Bilici; Bala Basak Oven Ustaalioglu; Mesut Seker; Nesrin Canpolat; Bulent Tekinsoy; Taflan Salepci; Mahmut Gumus
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

6.  Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Yasushi Kaji; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2008-04-19       Impact factor: 5.315

7.  Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Yasushi Kaji; Ichio Fukasawa; Noriyuki Inaba; Narufumi Suganuma; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.